Scholarlink

Background <p>Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the <i>GBA1</i> gene, leading to deficient glucocerebrosidase activity and accumulation of glucosylceramide in macrophages. Beyond lysosomal dysfunction, GD is associated with widespread metabolic abnormalities, yet the molecular basis of these changes remains incompletely understood. This study employed constraint-based genome-scale metabolic modelling to investigate systemic metabolic reprogramming in GD macrophages, aiming to uncover disrupted pathways and mechanistic drivers of disease phenotypes.</p> Results <p>A total of 150 pairs of high-quality macrophage-specific models under Gaucher and control conditions were developed using a semi-automated pipeline to integrate transcriptomic, exometabolomic and bibliomic data. These Gaucher models captured disease-specific perturbations by incorporating gene expression profiles from GD macrophages. Simulations predicted a shift from oxidative phosphorylation to glycolysis under energy stress in GD, attributed to impaired mitochondrial ATP transport and reduced activity of respiratory complexes. Lipid metabolism was profoundly altered, with increased <i>de novo</i> ceramide synthesis, defective ganglioside processing, and dysregulated cholesterol metabolism. Despite clinically observed hypocholesterolaemia, the models predicted upregulated intracellular cholesterol biosynthesis, suggesting a disconnect between intracellular and systemic cholesterol pools. Reporter metabolite analysis further highlighted cholesterol, sphingolipids, and acylcarnitine as hubs of transcriptional dysregulation. Robust metabolic transformation analysis predicted <i>ASAH1</i>(acid ceramidase) and <i>CPT1A</i> (carnitine palmitoyl transferase 1&#xa0;A) as potential modifier genes influencing lipid catabolism and mitochondrial function. Several model predictions were corroborated by independent experimental findings, supporting their biological plausibility.</p> Conclusions <p>This study demonstrates the utility of constraint-based metabolic modelling in elucidating the systems-level metabolic dysfunction underlying GD. The results highlight a core axis of mitochondrial and lipid metabolic disruption, particularly involving cholesterol homeostasis, as a central feature of disease pathophysiology. These predictions provide mechanistic insight into the cellular consequences of lysosomal dysfunction and identify candidate metabolic biomarkers and therapeutic targets. The modelling framework developed here supports hypothesis generation and future applications in precision medicine for lysosomal storage disorders.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Constraint-based modelling of metabolic dysregulation in Gaucher disease: mitochondrial dysfunction and disrupted cholesterol homeostasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Yanjun Liu,
  • Xi Luo,
  • Samira Ranjbar,
  • Johannes M. F. G. Aerts,
  • Martijn van der Lienden,
  • Andrea Dardis,
  • Ronan M. T. Fleming

摘要

Background

Gaucher disease (GD) is a lysosomal storage disorder caused by mutations in the GBA1 gene, leading to deficient glucocerebrosidase activity and accumulation of glucosylceramide in macrophages. Beyond lysosomal dysfunction, GD is associated with widespread metabolic abnormalities, yet the molecular basis of these changes remains incompletely understood. This study employed constraint-based genome-scale metabolic modelling to investigate systemic metabolic reprogramming in GD macrophages, aiming to uncover disrupted pathways and mechanistic drivers of disease phenotypes.

Results

A total of 150 pairs of high-quality macrophage-specific models under Gaucher and control conditions were developed using a semi-automated pipeline to integrate transcriptomic, exometabolomic and bibliomic data. These Gaucher models captured disease-specific perturbations by incorporating gene expression profiles from GD macrophages. Simulations predicted a shift from oxidative phosphorylation to glycolysis under energy stress in GD, attributed to impaired mitochondrial ATP transport and reduced activity of respiratory complexes. Lipid metabolism was profoundly altered, with increased de novo ceramide synthesis, defective ganglioside processing, and dysregulated cholesterol metabolism. Despite clinically observed hypocholesterolaemia, the models predicted upregulated intracellular cholesterol biosynthesis, suggesting a disconnect between intracellular and systemic cholesterol pools. Reporter metabolite analysis further highlighted cholesterol, sphingolipids, and acylcarnitine as hubs of transcriptional dysregulation. Robust metabolic transformation analysis predicted ASAH1(acid ceramidase) and CPT1A (carnitine palmitoyl transferase 1 A) as potential modifier genes influencing lipid catabolism and mitochondrial function. Several model predictions were corroborated by independent experimental findings, supporting their biological plausibility.

Conclusions

This study demonstrates the utility of constraint-based metabolic modelling in elucidating the systems-level metabolic dysfunction underlying GD. The results highlight a core axis of mitochondrial and lipid metabolic disruption, particularly involving cholesterol homeostasis, as a central feature of disease pathophysiology. These predictions provide mechanistic insight into the cellular consequences of lysosomal dysfunction and identify candidate metabolic biomarkers and therapeutic targets. The modelling framework developed here supports hypothesis generation and future applications in precision medicine for lysosomal storage disorders.

Graphical Abstract